FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and biochemistry. Presented is a monoclonal antibody specifically binding to human vascular endothelial growth factor receptor 1 (VEGFR-1) with high affinity.
EFFECT: invention provides suppression of intestinal tumour cell growth and possibility of using antibodies in preclinical studies for treating human intestinal cancer.
1 cl, 5 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST HUMAN STABILIN-1 RECEPTOR | 2023 |
|
RU2823309C1 |
| MONOCLONAL ANTIBODY TO THE C- TERMINAL FRAGMENT OF ANTI -MULLER HORMONE | 2021 |
|
RU2770003C1 |
| MONOCLONAL ANTIBODY AGAINST THE C-TERMINAL FRAGMENT OF ANTI-MULLERIAN HORMONE | 2021 |
|
RU2764795C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| ANAPHYLATOXIN C5A ANTIBODIES TO HUMAN | 2019 |
|
RU2731516C1 |
| MUS MUSCULUS HYBRID CULTIVATED ANIMAL CELLS STRAIN α - THE PRODUCER OF MONOCLONAL ANTIBODIES SPECIFIC TO THE CANCER-TESTICULAR ANTIGEN OF THE PERSON GAGE | 2017 |
|
RU2652885C1 |
| MONOCLONAL ANTI-IDIOTYPIC ANTIBODY AI-G1, HAVING ANTIGENIC PROPERTIES OF MORPHINE | 2019 |
|
RU2717989C1 |
| STRAIN OF HYBRID CULTIVATED CELLS OF ANIMALS Mus Musculus, PRODUCING MONOCLONAL ANTIBODIES, SPECIFIC TO PEPTIDE, WHICH POSSESSES APOPTOTIC ACTIVITY WITH RESPECT TO CANCER CELLS | 2009 |
|
RU2402605C1 |
| MUS MUSCULUS 5B9 HYBRID CULTIVATED ANIMAL CELLS- A PRODUCER OF MOUSE MONOCLONAL ANTIBODY 5B9, MONOCLONAL MOUSE ANTIBODY 5B9 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI5B9, NEUTRALIZING RICIN RICINUS COMMUNIS | 2022 |
|
RU2802436C1 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
